Blog
RSS FeedPosted by Michael Wonder on 12 Oct 2016
Terminal breast cancer patients denied life-extending drugs available in Australia
13 October 2016 - Time is invaluable to terminal breast cancer patient Tamara Malone. ...
Posted by Michael Wonder on 12 Oct 2016
Decision to award sole supply of venlafaxine
12 October 2016 - PHARMAC is pleased to announce a decision to award a sole supply arrangement for venlafaxine hydrochloride ...
Posted by Michael Wonder on 11 Oct 2016
Multi-product proposal involving nine pharmaceuticals
11 October 2016 - PHARMAC is seeking feedback on a proposal to fund three new treatments, widen access to three ...
Posted by Michael Wonder on 11 Oct 2016
Decision regarding funding of the HIV treatments dolutegravir (Tivicay) and abacavir sulphate with lamivudine (Kivexa)
11 October 2016 - PHARMAC is pleased to announce that the approval of an agreement with GlaxoSmithKline for the funding ...
Posted by Michael Wonder on 10 Oct 2016
New electronic portal for bidding on PHARMAC’s annual tender
10 October 2016 - New e-portal for PHARMAC’s annual tender now available to trial. ...
Posted by Michael Wonder on 02 Oct 2016
New Zealand Pharmaceutical Schedule - 1 October 2016 update
1 October 2016 - The October 2016 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 28 Sep 2016
Decision to not accept any proposals for the insulin glargine request for proposals
28 September 2016 - PHARMAC has decided not accept any proposals for the supply of insulin glargine following consideration of responses ...
Posted by Michael Wonder on 09 Sep 2016
Proposal relating to two HIV treatments (Tivicay and Kivexa)
9 September 2016 - PHARMAC is seeking feedback on a proposal to list a new treatment for HIV, dolutegravir (Tivicay) and ...
Posted by Michael Wonder on 05 Sep 2016
PHARMAC’s implementation of Trans-Pacific Partnership provisions and other amendments to application processes
5 September 2016 - PHARMAC is seeking feedback on our proposed approach to addressing New Zealand’s obligations under the Trans-Pacific Partnership ...
Posted by Michael Wonder on 05 Sep 2016
Proposal related to second & third-line anti-VEGF treatments for ophthalmic use
5 September 2016 - PHARMAC has entered into provisional agreements with Novartis and Bayer and is seeking feedback on a ...
Posted by Michael Wonder on 05 Sep 2016
Help shape the way PHARMAC implements TPP changes
5 September 2016 - PHARMAC is asking New Zealanders to help it make some changes to how medicine and medical device ...
Posted by Michael Wonder on 31 Aug 2016
Q&A: Is NZ lagging in cancer drug funding?
31 August 2016 - Researchers have called for an urgent overhaul of New Zealand's processes for funding cancer drugs to ensure ...
Posted by Michael Wonder on 31 Aug 2016
New Zealand Pharmaceutical Schedule - 1 September 2016 update
1 September 2016 - The September 2016 issue of the New Zealand Pharmaceutical Schedule sees the listing of one new ...
Posted by Michael Wonder on 30 Aug 2016
Decision to award sole supply to Zoladex and reference price Eligard and Lucrin
30 August 2016 - PHARMAC has made decisions to award the Zoladex brand of goserelin acetate sole subsidised supply in the ...
Posted by Michael Wonder on 28 Aug 2016
Cancer campaigner and melanoma patient Jeffrey Paterson dies aged 23
28 August 2016 - Young melanoma patient Jeffrey Paterson helped to win the campaign for Government funding of Keytruda, but didn't ...